With an unrivalled track record of solving research challenges, our highly experienced scientific team delivers successful outcomes efficiently and quickly.
We work closely and collaboratively with ambitious life science organisations globally. See what some of them have to say about working with Domainex:
Dr. Joon Seok Park - Chief of Drug Discovery Center, Daewoong Pharmaceutical Co., Ltd.
It has been a real delight and privilege to work with Domainex. Their expertise in medicinal chemistry has enabled us not only to explore novel technology but also to accelerate drug discovery process. Domainex management team provides professional, strong work ethic as well as transparent communication.
We would always welcome an opportunity to collaborate with Domainex.
Serena Kern-Libera - Founder, COO & General Counsel, LinkGevity
It has been a pleasure to collaborate with Domainex. Their commitment to data-driven approaches and rigorous science aligns perfectly with our own values. Together, we've tackled ambitious and cutting-edge work relating to our discovery of Anti-Necrotics™. Their responsiveness to evolving needs, combined with efficient execution, has been crucial to our shared success. We look forward to continuing this partnership and exploring future opportunities together.
Peter Bunyard - Director of Immunology, and Alessandro Mazzacani - R&D project Manager, Sitryx Therapeutics
Working with Domainex is a pleasure! The Domainex team have been integral to our project team - providing biology, crystallography and chemistry expertise in drug discovery that is highly valued by Sitryx. Their professionalism, friendliness, open communication style and approachability has meant we’ve been able to navigate our way through complex biology and challenging medicinal chemistry with maximum engagement and minimal frustration. Domainex employees have gone the extra-mile to accommodate difficult requests and have worked collaboratively and exhaustively to give our project the best possible chance of success.
Domainex team has demonstrated exceptional levels of customer service during our collaboration. Open communication with Domainex leadership has been a constant feature, ensuring alignment between resources allocation and project’s goals and timelines.
David Knight - Senior Scientist, DJS Antibodies
Working with Domainex on a PoLiPa project has enabled us to establish novel technologies. We were impressed with their willingness to be flexible away from their standard protocol to expedite timelines and we had a collaborative relationship with their protein scientists.
Dr Paul Little – CEO, Vesper Bio ApS
Vesper Bio has enjoyed an ongoing collaboration with Domainex for some years now. We have been impressed by their ability to generate important data in various complex assays and to provide important insights and analysis.
Dr Richard Bethell - Chief Development Officer, STipe Therapeutics
Having used Domainex as our primary provider of out-sourced chemistry for the last two years, we continue to be impressed by their professionalism: not only do they provide an effective synthetic chemistry service, but by communicating transparently, proposing new approaches to target compounds, and highlighting new external developments in relevant areas of medicinal chemistry, they contribute to the direction of our program while minimizing cycle times.
Dr Neil Miller - CEO, NRG Therapeutics
We chose Domainex as our lead CRO partner to support the lead optimisation phase of a neuroscience project funded by a Biomedical Catalyst Award from Innovate UK. Excellent progress has been made by the medicinal chemistry and biology teams at Domainex, and the project is on track to deliver its next milestone.
Paul Lehner FmedSci FRS - Professor of Immunology and Medicine, University of Cambridge
It was an absolute pleasure to work with Domainex on our medicinal chemistry, drug discovery project. The whole team were professional, responsive and incredibly effective. In a relatively short time period we achieved what would have taken at least twice as long with other companies. I couldn’t recommend them highly enough, and look forward to working with the Domainex team again.
Dr Dominic Tisi - Director, Molecular Sciences, Astex Pharmaceuticals
We have worked with Domainex on several structural biology projects over the past 3 years. The Domainex team have coupled high quality science with effective communication and have been efficient in delivering timely and impactful results on proteins from multiple, challenging, target classes.
Professor Helen Philippou - Professor of Translational Medicine, Lunac Therapeutics
Domainex have provided us with integrated drug discovery services including medicinal chemistry, assay biology and ADME. The team were great to work with in a collaborative partnership. The scientists have contributed strategic insight and intellectual input across a range of disciplines. This support was invaluable in areas of expertise on the overall drug discovery process. I’ve really enjoyed working together with such a dedicated, highly skilled and professional team.
I would recommend Domainex to anyone looking for a provider of drug discovery services.
Professor Daniel Longley – Deputy Director of the Patrick G. Johnston Centre for Cancer Research, Queen’s University Belfast
It has been an absolute pleasure working with Dr Boffey and the Domainex team on this project. Without their first class medicinal chemistry expertise and the use of their Leadbuilder virtual screening platform at the outset of the programme, we would not have been able to secure the support of The Wellcome Trust and advance the programme to the stage it has now reached.
Marc Gleeson – CEO, Azura Ophthalmics
Domainex with their deep industry experience, have been able to solve complex synthetic, medicinal and analytical chemistry challenges to deliver project outcomes for Azura in a timely and efficient manner. They’ve been able to flexibly resource our program to deliver high quality results and support tight patent timelines.
Dr Rich Boyce – Senior Director of Research, PhoreMost Ltd.
Domainex is a highly valuable partner in PhoreMost’s drug discovery programmes. The company’s expertise in virtual screening, through its LeadBuilder Platform, has allowed the identification of small molecule hits to challenging biological targets which are now being pursued at PhoreMost.
Domainex’s deep knowledge and expertise in computational chemistry is enabling us to progress multiple projects quickly and cost effectively.